The Study of Cardiac Damage and the Risk of Leukemia in MS Patients Treated with Stem Cells

Multiple Sclerosis (MS) is a neurodegenerative disease that affects the brain and spinal cord. Cellular transplantation, from bone marrow or other sources, can be an effective treatment for people with certain types of cancer, such as leukemia and lymphoma. Cell transplantation is used to treat many myeloma and neuroblastoma and those with other types of cancer. The purpose of transplantation or bone marrow transplantation is to suppress the immune system with chemotherapy after the end of the radiation. After successful transplantation, bone marrow begins to form a new blood cells. Pubmed and Google Scholar search engines were searched for Multiple Sclerosis , StemCells , Treatment and Leukemia , and the review articles of the last 5 years (2015-2019) were selected. Out of the total 490 articles found, 372 articles were only available in Abstract form and 118 articles were presented in full text from which 20 articles fully associated with thetitle were selected for the study. It is said that in addition to stopping the disease, a treatment through autologous hematopoietic stem cell transplantation (HSCT) heals injuries in the body. It is necessary to check the validity of this theory. To achieve this goal, it is necessary tocarefully examine the effects of this therapeutic approach on important organs of the body such as the heart, the brain and on the probability of developing cancers such as leukemia. It is worth mentioning that immunosuppressive drugs are used for MS a powerful example of which is Mitoxantrone. According to some reports acute myeloid leukemia has been previously seen in people treated with Mitoxantrone for MS or cancer. The aim of this study is to check the risk of leukemia and heart disease in MS patients cured with HSCT.